Background: • Appropriate thromboprophylaxis for patients at-risk can reduce the incid ence of venous thromboembolism (VTE).
• In recent years, the incidence of VTE has been increasing in China. This suggests that despite the American College of Chest Physicians (ACCP) guideline’s recommendations, utilization of anticoagulants is suboptimal.
• Active cancer is one of the risk factors of VTE. Hence, improvement of awareness and practice of VTE prophylaxis in the medical oncology inpatients is urgently needed.
Aims: To investigate the risk profile of VTE and evaluate VTE prophylaxis implementation in patients with cancer in China.
Methods: DissolVE-2 was a retrospective, multicenter, observational, cross-sectional study enrolling 14000 patients in China. Here we report the results from the subgroup analysis in patients with cancer.
Results: A total of 1535 patients with cancer were included. According to the Padua score, 826 (53.8%) patients were at low risk of VTE, while 709 (46.2%) patients were at high VTE risk. Among patients with high VTE risk, 93.9% did not receive any VTE prophylaxis, and only 11 (1.6%) patients received appropriate VTE prophylaxis as per ACCP guidelines. VTE events occurred in 9 (0.6%; 4 and 5 patients in the low and high VTE risk group respectively) patients during hospitalization.Among high risk patients who received VTE prevention, no VTE events were observed.(Table 1) A total of 55 (3.6%) patients (24 patients with low risk of bleeding, 31 patients with higher risk of blood) occurred bleeding events. (Table 2) 53 patients were identified as unrelated to VTE therapy and 2 patients could not be determined. VTE events in medical patients with cancer during hospitalization
Bleeding events in medical patients with cancer
Conclusions: Nearly half of the in-patients with cancer were at high risk of VTE, but most of them did not receive VTE prophylaxis. This real-world data highlights an urgent need to increase awareness and appropriate VTE prophylaxis in China to improve the management of VTE risk in oncology inpatients.
To cite this abstract in AMA style:
Xu R, Shi Y, Gao Y, Zhai Z, Li W, Qin X, Qu J, Wang C. Venous Thromboembolism Risk Profiles and Prophylaxis in Medical Oncology Inpatients: a Subgroup Analysis of the Observational DissolVE-2 Study [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/venous-thromboembolism-risk-profiles-and-prophylaxis-in-medical-oncology-inpatients-a-subgroup-analysis-of-the-observational-dissolve-2-study/. Accessed November 29, 2023.« Back to ISTH 2021 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/venous-thromboembolism-risk-profiles-and-prophylaxis-in-medical-oncology-inpatients-a-subgroup-analysis-of-the-observational-dissolve-2-study/